A Phase 2 program evaluating ZT002 for chronic weight management
Latest Information Update: 16 Sep 2024
At a glance
- Drugs ZT 002 (Primary)
- Indications Obesity
- Focus Therapeutic Use
- 16 Sep 2024 New trial record
- 12 Sep 2024 According to QL Biopharmaceutical media release, a Phase 2 program evaluating ZT002 for chronic weight management has been initiated in China and regulatory interaction is planned with U.S. FDA to advance the program outside China.